Research

Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

Xabier Agirre,¹ Giancarlo Castellano,² Marien Pascual,¹ Simon Heath,³ Marta Kulis,² Victor Segura,⁴ Anke Bergmann,⁵ Anna Esteve,³ Angelika Merkel,³ Emanuele Raineri,³ Lidia Agueda,³ Julie Blanc,³ David Richardson,⁶ Laura Clarke,⁶ Avik Datta,⁶ Nuria Russiñol,² Ana C. Queirós,² Renée Beekman,² Juan R. Rodríguez-Madoz,¹ Edurne San José-Enériz,¹ Fang Fang,⁷ Norma C. Gutiérrez,⁸ José M. García-Verdugo,⁹ Michael I. Robson,¹⁰ Eric C. Schirmer,¹⁰ Elisabeth Guruceaga,⁴ Joost H.A. Martens,¹¹ Marta Gut,³ Maria J. Calasanz,¹² Paul Flicek,⁶ Reiner Siebert,⁵ Elías Campo,² Jesús F. San Miguel,¹³ Ari Melnick,⁷ Hendrik G. Stunnenberg,¹¹ Ivo G. Gut,³ Felipe Prosper,^{1,13,14} and José I. Martín-Subero^{2,14}

¹Area de Oncología, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; ²Unidad de Hematopatología, Servicio de Anatomía Patológica, Hospital Clínic, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; ³Centro Nacional de Análisis Genómico, Parc Científic de Barcelona, 08028 Barcelona, Spain; ⁴Unidad de Bioinformática, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain; ⁵Institute of Human Genetics, Christian-Albrechts-University, 24105 Kiel, Germany; ⁶European Bioinformatics Institute, European Molecular Biology Laboratory, Cambridge, CB10 1SD, United Kingdom; ⁷Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York 10065, USA; ⁸Hospital Universitario de Salamanca, 37007 Salamanca, Spain; ⁹Department of Cellular Morphology, University of Valencia, Unidad Mixta CIPF-UVEG, CIBERNED, 46100 Valencia, Spain; ¹⁰The Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, EH9 3BF, United Kingdom; ¹¹Department of Molecular Biology, Faculty of Science, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen, 6500 HB Nijmegen, The Netherlands; ¹²Departamento de Genética, Universidad de Navarra, 31008 Pamplona, Spain; ¹³Clínica Universidad de Navarra, Universidad de Navarra, 31008 Pamplona, Spain

While analyzing the DNA methylome of multiple myeloma (MM), a plasma cell neoplasm, by whole-genome bisulfite sequencing and high-density arrays, we observed a highly heterogeneous pattern globally characterized by regional DNA hypermethylation embedded in extensive hypomethylation. In contrast to the widely reported DNA hypermethylation of promoter-associated CpG islands (CGIs) in cancer, hypermethylated sites in MM, as opposed to normal plasma cells, were located outside CpG islands and were unexpectedly associated with intronic enhancer regions defined in normal B cells and plasma cells. Both RNA-seq and in vitro reporter assays indicated that enhancer hypermethylation is globally associated with down-regulation of its host genes. ChIP-seq and DNase-seq further revealed that DNA hypermethylation in these regions is related to enhancer decommissioning. Hypermethylated enhancer regions overlapped with binding sites of B cell-specific transcription factors (TFs) and the degree of enhancer methylation inversely correlated with expression levels of these TFs in MM. Furthermore, hypermethylated regions in MM were methylated in stem cells and gradually became demethylated during normal B-cell differentiation, suggesting that MM cells either reacquire epigenetic features of undifferentiated cells or maintain an epigenetic signature of a putative myeloma stem cell progenitor. Overall, we have identified DNA hypermethylation of developmentally regulated enhancers as a new type of epigenetic modification associated with the pathogenesis of MM.

[Supplemental material is available for this article.]

¹⁴Senior authors.

Corresponding authors: xaguirre@unav.es, fprosper@unav.es, imartins@clinic.ub.es

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.180240.114>.

© 2015 Agirre et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Multiple myeloma (MM) is an aggressive and incurable neoplasm characterized by clonal proliferation of plasma cells in the bone marrow and a marked clinico-biological heterogeneity (Morgan et al. 2012; Bergsagel et al. 2013). MM frequently arises from a pre-malignant state known as monoclonal gammopathy of undetermined significance (MGUS), although the precise molecular mechanisms involved in the progression from MGUS to MM are only partially understood. Various distinct genetic abnormalities have been observed in both MM and MGUS, including gene mutations, chromosomal rearrangements, or aneusomies (Bergsagel and Kuehl 2005; Chng et al. 2006; Chapman et al. 2011).

Besides genetic abnormalities, recent studies have shown that epigenetic changes such as DNA methylation play an important role in MM. Various reports indicate that DNA methylation patterns are capable of distinguishing normal plasma cells (NPCs) from MGUS and MM cells. The major differences between these entities can be explained by the occurrence of DNA hypomethylation in malignant plasma cells (Salhia et al. 2010; Walker et al. 2011; Heuck et al. 2013). In addition to this DNA hypomethylation, some studies have demonstrated aberrant DNA hypermethylation of promoter regions of different tumor suppressor genes in MM, although the classical CpG island methylator phenotype (CIMP) extensively observed in a wide variety of tumors (Issa 2004) has been rarely reported in MM (Martin et al. 2008). Hypermethylation of *RASD1*, for example, has been correlated with resistance of MM to dexamethasone (Nojima et al. 2009). Inappropriate DNA methylation of *TNFRSF18* (also known as *GITR*) (Liu et al. 2013), *MIR34B/C* (Wong et al. 2011), or the combined inactivation of genes *GPX3*, *RBP1*, *SPARC*, and *TGFBI* (Kaiser et al. 2013) have been associated with poor prognosis, survival, and disease progression in patients with MM.

In spite of these significant findings, the high-throughput DNA methylation reports published so far in MM were restricted to the study of promoter regions (Nojima et al. 2009; Salhia et al. 2010; Walker et al. 2011; Heuck et al. 2013; Kaiser et al. 2013). Hence, the purpose of our study was to adopt a more extensive and unbiased analysis of the DNA methylome, including promoters, gene bodies, and intergenic regions in normal plasma cells (NPC) and plasma cells from MGUS and MM patient samples. Using this approach, we have identified that DNA methylation of B cell-specific enhancer regions is a new phenomenon associated with MM pathogenesis.

Results

The DNA methylome of MM is globally characterized by a large degree of heterogeneity

To analyze the DNA methylome and define general epigenetic signatures associated with plasma cell disorders, we applied the HumanMethylation450 BeadChip (Illumina) to purified plasma cells obtained from bone marrow samples of MM ($n=104$) and MGUS ($n=16$) patients as well as normal bone marrows ($n=3$ pools from four donors each) and nontumoral tonsils ($n=8$) (Supplemental Table 1). Unsupervised principal component analysis of the normalized DNA methylation data identified a clear distinction between NPC and MM samples, with a larger degree of heterogeneity in the myeloma plasma cells (Fig. 1A,B; Supplemental Fig. 1). Next, we further characterized this heterogeneity of MM by comparing it with other lymphoid malignancies. We calculated the median methylation value per case and measured the variability per entity. The coefficient of variation (CV) was significantly

higher ($P<0.001$) in MM (CV = 30.7) than in acute lymphoblastic leukemia (ALL; CV = 7.9), chronic lymphocytic leukemia (CLL; CV = 5.3), and diffuse large B cell lymphoma (DLBCL; CV = 10.4) (Fig. 1C). This analysis shows that the extreme heterogeneity of DNA methylation levels seems to be an epigenetic feature that is specific for MM. To further characterize this variable pattern, we sequenced the whole DNA methylome at a single base pair resolution (>51-fold coverage per sample) of NPCs from bone marrow and two MMs in which the HumanMethylation450 BeadChip indicated extreme hyper- or hypomethylation (white arrows in Fig. 1B; Supplemental Tables 1, 2; Supplemental Fig. 1). Indeed, these analyses validated the array data at the whole-genome level, with the genome of MM1 being hypermethylated and that of MM2 being hypomethylated as compared to NPCs (Fig. 1D–F). Hence, MM can show different methylomes, with a wide range of methylation levels that range from globally hypo- to hypermethylated.

Detection of aberrant DNA methylation in MM and MGUS

To obtain a reliable whole-genome measure of the magnitude of epigenetic changes in MM, we compared the methylation levels of each MM sample with extreme methylation patterns and NPCs. Sample MM1 showed 1,504,700 differentially methylated regions (DMRs) covering a total of 2,158,824 CpG dinucleotides, whereas MM2 had 1,875,824 DMRs covering 4,308,958 CpGs. As previously suggested in Figure 1D, the majority of DMRs identified in MM2 were hypomethylated, whereas MM1 showed less hypomethylation and increased hypermethylation levels (Fig. 2A,B).

Next, we attempted to generate a consensus differential methylation signature of MGUS and MM in comparison with NPCs, using microarray data of a large series of samples (Fig. 2C–E). From 78,998 differentially methylated CpGs identified between MM and NPC, the great majority were hypomethylated (98.3%). In MGUS, we detected 9388 differentially methylated CpGs, of which 6874 (73.2%) were hypomethylated and 2514 (26.8%) hypermethylated (Fig. 2C–E; Supplemental Fig. 2). A direct comparison between MM and MGUS revealed that the progression from MGUS to MM seems to be associated with increased hypomethylation in the absence of additional hypermethylation events (Supplemental Fig. 3).

Applying an unsupervised analysis in order to compare the DNA methylation profiles of clinically relevant MM subtypes based on the presence or absence of cytogenetic alterations, i.e., hyperdiploidy, chromosomal translocations affecting the immunoglobulin heavy chain (*IGH*) locus and *TP53* deletions, we did not find any apparent association (Fig. 1B; Supplemental Fig. 4). These results were confirmed using a supervised approach, in which we observed only a few differentially methylated CpGs between cytogenetic subgroups (Supplemental Fig. 5). However, these findings do not rule out the possibility that other genetic aberrations, not analyzed in our study, may be related to DNA methylation changes, as shown previously in MM as well as in other tumors (Weisenberger et al. 2006; Walker et al. 2011).

Hypo- and hypermethylated CpGs in MM are located in specific genomic regions and enriched in particular chromatin states

Hypomethylated sites in MM and MGUS mainly occurred in regions lacking CpG islands (CGI) and were predominantly located in gene bodies and intergenic regions. Although both whole-genome bisulfite sequencing (WGBS) and HumanMethylation450 BeadChip showed this effect, the enrichment, when compared with the background distribution, was particularly evident in the

Figure 1. Whole-genome DNA methylation data of neoplastic and normal plasma cells. (A) Principal component analysis of HumanMethylation450 BeadChip data in MGUS, MM, and NPC from tonsils or bone marrow. (B) Unsupervised hierarchical clustering analysis of MM and MGUS patient samples as well as NPC samples from tonsil or bone marrow from healthy donors (the 20,000 CpG sites with most variable methylation values were used for this analysis). (HyperD) Hyperdiploid MM sample; [t(IGH)] MM sample with *IGH* translocation; [del(17p53)] MM sample with deletion of *TP53*. (C) Bar plot showing the coefficient of variation of median methylation values per case in ALL, CLL, DLBCL, MGUS, and MM. (D) Circular representation of DNA methylation levels of purified plasma cells of two MM patient samples (MM1 and MM2) compared to purified NPC obtained from bone marrow from healthy donors. Histograms represent CpG methylation levels averaged in 10-Mbp genomic windows. This representation with low resolution indicates that the shift of methylation levels in MM1 and MM2, as compared to NPC, takes place throughout the genome and not only in particular chromosomal regions. (E,F) Scatter plots and density codes for DNA methylation data of all autosomes. Pairwise comparisons of MM1 and MM2 sample to NPC (E) and MM2 sample to NPC (F) are shown.

Figure 2. Differential DNA methylation in MM and MGUS as compared to NPCs. (A,B) Differentially methylated CpGs using WGBS data in (A) MM1 versus NPC and (B) MM2 versus NPC. (C,D) Differentially methylated CpGs identified using the HumanMethylation450 BeadChip data in (C) MGUS versus NPC samples and (D) MM versus NPC samples. (E) Heatmap of significantly hypomethylated (left) or hypermethylated CpGs (right) in MM samples versus NPC samples. (F) Relative distribution of differentially hypo- or hypermethylated CpGs across different functional chromatin states of the genome using WGBS data (left) or HumanMethylation450 BeadChip data (right) as compared to their respective backgrounds (first column). The numbers inside each cell point to the percentage of CpGs belonging to a particular chromatin state. (WG) Whole-genome; (HyperM) hypermethylated CpGs; (HypoM) hypomethylated CpGs.

consensus signature (MM versus NPCs) derived from HumanMethylation450 BeadChip. Interestingly, hypermethylated sites also occurred in regions lacking CGIs (Supplemental Fig. 6).

In order to investigate the functional significance of aberrant DNA methylation in MM, we annotated hypo- and hypermethylated CpGs according to functional chromatin states recently described by ChIP-seq in immortalized mature B cells (IMBCs) (Ernst et al. 2011), which have a DNA methylation profile similar to normal memory B cells and plasma cells (Supplemental Fig. 7). As previously observed in colon cancer (Berman et al. 2011), the great majority (75%–80%) of hypomethylated CpGs in MM and MGUS, or those losing methylation in the progression from MGUS to MM, were located in heterochromatic and late-replicating regions such as lamina-associated domains (LADs) (Fig. 2F; Supplemental Figs. 3, 8). We analyzed the potential effect of this epigenetic change and we found neither a morphological alteration of the chromatin bound to the nuclear lamina by electron microscopy nor a detachment of hypomethylated regions from the nuclear lamina by 3D-FISH. We then studied the transcriptome of 11 MM cases and four NPCs by RNA-seq, and we observed that genes located in hypomethylated heterochromatic regions globally showed low expression levels both in NPCs and MMs regardless of their methylation status (Supplemental Fig. 9). Furthermore, focusing only on promoter regions undergoing demethylation, only 1.9% of the CpGs showed a significant correlation ($P < 0.01$) with gene expression. These data suggest that heterochromatin hypomethylation seems to have a low impact on gene expression.

Remarkably, a large proportion of hypermethylated CpGs in MM ($n = 794$; 59.9%; $P < 1 \times 10^{-12}$) (Supplemental Table 3) and MGUS ($n = 1656$; 65.9%; $P < 1 \times 10^{-12}$) were located within enhancer regions (Figs. 2F, 3A; Supplemental Fig. 10), and in partic-

ular, within intronic enhancers (Supplemental Fig. 11). To evaluate whether differential methylation of enhancers in MM may be functionally relevant, we analyzed the expression of their associated genes by RNA-seq. Overall, we observed a shift toward an inverse correlation between enhancer methylation and their associated gene expression as compared to nonenhancer intronic regions of the same genes (Fig. 3B–F; Supplemental Table 4), which mostly took place in the absence of DNA methylation changes in the corresponding promoter regions (Supplemental Fig. 12). In fact, of the 50 genes with the strongest inverse correlation between enhancer methylation and gene expression, only two (4%) showed concurrent promoter hypermethylation. We further analyzed the consequences of differential DNA methylation at enhancer regions and observed that treating a MM cell line with 5-azacytidine led to increased expression of *SLC15A4* and *PVT1* (Supplemental Fig. 13). Due to the unspecificity of this pharmacological treatment, we also performed reporter assays using a CpG-Free Luciferase Vector (Klug and Rehli 2006). We cloned three enhancer regions into this vector, which showed variable levels of correlation between DNA methylation and expression levels (Supplemental Table 5). Luciferase activity analyzed in transient transfection assays comparing unmethylated and in vitro methylated vectors revealed that upon enhancer methylation, the luciferase activity was reduced, further supporting our findings in primary tumors (Fig. 3D–F).

Hypermethylation of B cell-specific enhancers in MM is associated with enhancer decommissioning

After showing that DNA methylation is related to enhancer activity, we attempted to analyze the biological function of the genes

Figure 3. Functional and transcriptional analysis of hypermethylated enhancer regions in MM. (A) Percentage of hypermethylated CpGs associated with enhancer regions in MGUS and MM patient samples using HumanMethylation450 BeadChip data. (B) Density plot of correlation coefficients between methylation levels of hypermethylated enhancers and the expression of their associated genes (cyan) using RNA-seq data. As control, intronic CpGs of the same genes were studied excluding the enhancer associated ones (black dotted line). For this analysis, we used 663 CpGs (out of 794) annotated to 574 genes with available gene expression, and 8956 CpGs in nonenhancer intronic regions of the same genes. (C) A snapshot of the UCSC Genome Browser showing the promoter (left) and the 3' intronic enhancer region (right) of the *SLC15A4* gene. Displayed tracks include the chromatin state characterization in IMBCs and ChIP-seq data for H3K27ac, H3K4me1, and H3K4me3. DNA methylation levels of NPCs and MM patient samples measured by WGBS and HumanMethylation450 BeadChip are also shown. (D–F) Correlation analysis between DNA methylation levels of the hypermethylated enhancers and expression of the associated gene (left). In addition, we display the luciferase reporter activity data of the analyzed enhancer region (right) located in the intron of (D) *SLC15A4*, (E) *PVT1*, and (F) *NCOR2*. (MP) Minimal promoter; (MET) methylated; (UNMET) unmethylated.

with hypermethylated enhancers (631 genes associated with the 794 CpGs). A Gene Ontology analysis pointed to significant enrichment of various terms associated with B-cell differentiation (Supplemental Table 6). Furthermore, using transcription factor binding sites (TFBSs) identified by ChIP-seq in the ENCODE Project (Gerstein et al. 2012), we observed that hypermethylated enhancers overlapped with binding sites of transcription factors (TFs) associated with B-cell differentiation such as BCL11A, BATF, EBF1, and PAX5 (Supplemental Table 7). These data led us to investigate whether the DNA methylation levels of these enhancer regions are modulated during normal B-cell differentiation. We analyzed the DNA methylation profiles of seven B-cell differentiation stages, including hematopoietic multipotent progenitors, several immature B cells, naive B cells, germinal center B cells, and plasma cells. In addition, we included embryonic stem cells (ESCs) and IMBCs (Ernst et al. 2011) in the analysis, as well as other B-cell neoplasms such as CLL ($n = 139$) (Kulis et al. 2012), ALL ($n = 46$) (Busche et al. 2013), and DLBCL ($n = 40$). Surprisingly, the 794 enhancer-associated CpGs hypermethylated in MM were also methylated in ESCs and gradually lost DNA methylation, finally becoming completely unmethylated in germinal

center B cells and terminally differentiated plasma cells (Fig. 4A). We found that ALLs appear to maintain a methylation pattern resembling their cellular origin (precursor B cell), whereas DLBCLs, similarly to MM, show hypermethylation of B cell-specific enhancers when compared to their cell of origin (i.e., germinal center B cells) (Supplemental Fig. 14).

Next, we studied whether enhancer hypermethylation in MM was accompanied by a change in the chromatin state. We performed ChIP-seq with antibodies against monomethylated lysine 4 (H3K4me1) and acetylated lysine 27 (H3K27ac) of histone H3 in NPCs and in the MM cell line U266, and also DNase-seq in the latter. Data were compared to ESCs (showing hypermethylated enhancers, similar to MM) and IMBCs (with unmethylated enhancers, similar to NPCs). As shown in Figure 4B, the genomic areas surrounding unmethylated enhancers in IMBCs show a clear enrichment of H3K4me1 and H3K27ac as well as DNase hypersensitive sites. In NPCs, the regions under study lost H3K27ac, but H3K4me1 showed a strong signal, indicating that they maintain their enhancer status. In contrast, methylated enhancers in ESCs and the U266 cell line actually represent decommissioned enhancers (Whyte et al. 2012; Rivera and Ren 2013) lacking all the

Figure 4. DNA methylation and chromatin features of hypermethylated enhancers in MM in the context of normal B-cell differentiation. (A) DNA methylation levels of 794 enhancer-associated CpGs in seven B-cell differentiation stages, MGUS and MM patient samples, as well as ESCs (H1), IMBCs (GM12878), and U266-MM cell lines. (B) ChIP-seq levels of H3K4me1 and H3K27ac, and DNase-seq data of 794 enhancer-associated CpGs in ESCs, IMBCs, NPCs, and the U266 MM cell line. (C) Density plot of H3K4me1, H3K27ac, and DNase levels in ESCs, IMBCs, NPCs, and the U266 MM cell line. Among the 794 enhancer-associated CpGs in MM, those hypermethylated in U266 are shown in the *top* panel, whereas those unmethylated in this cell line appear at the *bottom*. (MPP-CLP) Hematopoietic multipotent progenitors—common lymphoid progenitors; (ESCs) embryonic stem cells; (IMBCs) immortalized mature B cells; (NPCs) normal plasma cells; (U266-MM) multiple myeloma derived cell line U266.

enhancer-associated features (Fig. 4B,C). Interestingly, 125 of the 794 enhancers with significant hypermethylation in MM cases were unmethylated in the U266 MM cell line. Similarly to IMBCs, these unmethylated B-cell enhancers were accompanied by a chromatin structure linked to active enhancers in the MM cell line (Fig. 4C). This finding is further supported by the fact that enhancers (defined as such in IMBCs) hypomethylated in IMBCs, NPCs, and the MM cell line, but hypermethylated in ESCs, only showed active enhancer-related chromatin marks in the first three (Supplemental Fig. 15).

Down-regulation of B cell-specific transcription factors in MM is associated with enhancer hypermethylation

All the preceding results suggest that MM acquire hypermethylation in enhancer regions that paradoxically undergo demethylation during normal B-cell differentiation (Fig. 4A). Since the process of B-cell differentiation is guided by expression of stage-specific TFs (Matthias and Rolink 2005; Kurosaki et al. 2010), the binding of TFs to their target enhancers may result in demethylation. Several lines of evidence support this model in which DNA demethylation during cell development is mediated by the presence of TFs, whose binding may block DNA methylation maintenance after cell division (Stadler et al. 2011; Lee et al. 2012;

Feldmann et al. 2013; Hon et al. 2013; Kulis et al. 2013). Interestingly, here we have observed the reverse process in plasma cell disorders in which B cell-specific TF binding sites seem to reacquire a chromatin state that is typical of undifferentiated cells. Therefore, we postulate that down-regulation of B cell-specific TFs in MM cells could result in enhancer methylation and decommissioning. To test this hypothesis, we analyzed the expression levels of B cell-specific TFs in MMs and NPCs by RNA-seq and correlated them with the mean DNA methylation level of the enhancers with altered methylation in MM. Interestingly, for most of the B cell-specific TFs, we observed an inverse correlation between their expression and methylation levels of their target enhancers (Fig. 5A). Among these, the expression of *STAT5*, *PAX5*, *NFATC1*, and *BATF* showed a significant negative correlation with DNA methylation levels of enhancers in normal and neoplastic plasma cells (Pearson coefficient ranging from -0.79 to -0.62 , $P < 0.05$) (Fig. 5A–D; Supplemental Table 8). Furthermore, variable expression of several of these TFs was coordinated in MM patients (Fig. 5E), suggesting that the expression level of a TF network, and not that of individual TFs, was associated with the methylation levels of enhancers. In line with this finding, the expression levels of genes regulated by enhancer methylation also showed a correlated expression among MM patients (Supplemental Fig. 16).

Figure 5. B cell-specific TFs' expression correlates with DNA methylation levels of their binding sites in MM. (A) The upper part shows that hypermethylated enhancers are enriched for binding sites of B cell-specific TFs. The lower part displays the correlation coefficients between TF expression and mean DNA methylation level of their respective binding sites with hypermethylation in MM. (*) $P < 0.05$. (B–D) Scatter plots showing the association between TF expression and mean methylation level of their respective binding sites. Normal plasma cells are shown in blue and multiple myeloma samples are depicted in red. (E) Correlation matrix of expression levels of TFs among the 11 MM cases with available RNA-seq data. Only those TFs from A with at least 1.5-fold enrichment (in log₂) were used for this analysis.

Discussion

In this study, we have characterized the DNA methylome of normal and neoplastic plasma cells using a double approach. On the one hand, we generated an epigenetic signature of common DNA methylation changes in MGUS and MM by comparing

them to NPCs, using the HumanMethylation450 BeadChip in a large series of patients. On the other hand, we analyzed the whole DNA methylome at single base-pair resolution of two samples from the extremes of the DNA methylation spectrum of MM. This second approach allowed us to characterize the epigenetic heterogeneity in MM, to define the boundaries of DMRs, and to

measure the magnitude of DNA methylation changes in MM at the whole-genome level.

As shown in other studies (Salhia et al. 2010; Walker et al. 2011; Heuck et al. 2013), we describe a clear distinction in DNA methylation patterns between malignant and normal plasma cells, mostly in the form of hypomethylation in the former. Interestingly, one of the major features of MM is the extreme heterogeneity of median DNA methylation levels, which ranges from globally hypo- to globally hypermethylated as compared to NPCs. This heterogeneity in MM is remarkably higher than in other malignancies of the B-cell lineage (Fig. 1C). Premalignant MGUS samples were less heterogeneous than MM but shared a similar hypermethylation signature. In contrast, hypomethylation in MM was much more extensive and heterogeneous than in MGUS, suggesting that it may be related to progression from MGUS to MM, as previously reported (Salhia et al. 2010; Walker et al. 2011; Heuck et al. 2013). In contrast to other studies (Walker et al. 2011), we did not observe the epigenetic variability in MM to be associated with particular genetic changes. However, we cannot rule out the possibility that some genetic features, not analyzed in our study, could be correlated with the heterogeneous DNA methylome. Although the causes of epigenetic heterogeneity in MM require further investigation, we postulate that this phenomenon could be the consequence of both the DNA methylation pattern of the founder plasma cell clone within the heterogeneous plasma cell pool and the proliferative history of the neoplastic cells in a particular case.

One of the most unexpected findings of our study is that DNA hypermethylation in MGUS and MM occurred in regions outside CGIs. This finding contrasts with the classical cancer-associated CIMP (Issa 2004; Fang et al. 2014) and recent whole-methylome reports, in which hypermethylation is invariably associated with CGIs and CGI shores close to promoter regions (Berman et al. 2011; Hansen et al. 2011; Kulis et al. 2012). Remarkably, a large proportion of hypermethylated CpGs in MM and MGUS were located within intronic regions with enhancer-related chromatin marks in nonmalignant mature B cells and plasma cells. Analyzing the methylation of these regions in the context of B-cell differentiation, we observed a gradual demethylation from stem cells to plasma cells. Hence, the observed methylation pattern of these regions in MM is similar to undifferentiated precursor and stem cells. This finding may reveal new potential insights in the biology of the disease. On the one hand, it may represent a *de novo* epigenetic reprogramming in MM, leading to the acquisition of a methylation pattern related to stemness. On the other hand, we cannot rule out that the observed pattern could reflect an epigenetic imprint of initial premalignant phases of the disease in progenitor cells.

Our analysis of the chromatin in B cells, plasma cells, and MM revealed that enhancer hypermethylation in MM was associated with enhancer decommitment, as recently shown in prostate and breast cancer (Taberlay et al. 2014). Several studies have provided evidence indicating that the binding of specific TFs mediates the loss of DNA methylation at regulatory elements during the cell differentiation (Stadler et al. 2011; Lee et al. 2012; Feldmann et al. 2013; Hon et al. 2013; Kulis et al. 2013). Here, we have observed that the hypermethylation and decommitment of specific B-cell enhancers in MM appear to be related to down-regulation of a network of B-cell TFs. Similarly to the globally heterogeneous methylation pattern, this hypermethylation of B-cell enhancers also varied among different cases and may be useful to detect disease subtypes. Interestingly, ~20% of the MM patients express the

B-cell marker CD20 (San Miguel et al. 1991). We speculate that this MM subtype may lack hypermethylation and decommitment of B-cell enhancers, allowing part of the B-cell signature to be maintained. In conclusion, our results suggest that MM shows a widely heterogeneous DNA methylation pattern. Embedded into an extensive hypomethylated genome, we identified DNA hypermethylation of developmentally regulated enhancers as a new epigenetic feature of MM. The delineation of the precise role of enhancer hypermethylation in MM pathogenesis and its potential usefulness in the clinical setting as a new source of epigenetic biomarkers should be further investigated.

Methods

Patient samples and cell line

Purified plasma cells from bone marrow aspirations were obtained from newly diagnosed patients of MM ($n = 104$) and MGUS ($n = 16$). As negative controls, we purified plasma cells from healthy donors (eight tonsils and 12 bone marrows, the latter pooled into three samples of four donors each). The MM cell line U266 was kindly provided by Dr. Cigudosa (Spanish National Cancer Centre-CNIO, Madrid, Spain). Further details on the biological materials used in our study are described in the Supplemental Material.

DNA methylation analysis

Whole-genome bisulfite sequencing and HumanMethylation450 BeadChip (Illumina) were carried out in order to analyze the DNA methylation profile of MM, MGUS, normal plasma cells, and the U266 MM cell line. Details on the experimental procedures, annotation of CpG sites, detection of differentially methylated regions, and Gene Ontology analysis are described in the Supplemental Material.

Analysis of RNA-seq data

RNA samples from 11 MMs (also analyzed by HumanMethylation450 BeadChip) and four NPCs from tonsils were sequenced using the standard Illumina protocol. Technical details are described in the Supplemental Material.

Luciferase reporter assay

pCpGL empty vector and pCpGL-CMV/EF1 were kindly provided by Dr. Rehli (University Hospital, Regensburg, Germany). To properly initiate the transcription, a CpG free minimal promoter (5'-AGAGGGTATATAATGGAAGCTTAACCTCCAG-3') was also cloned in the pCpGL empty vector (see details in the Supplemental Material).

ChIP-seq and DNase-seq

ChIP-seq was performed in NPCs and in the U266 cell line, and DNase-seq was carried out only on the latter. Standard protocols generated within the Blueprint Consortium were followed. Protocol details can be found at <http://www.blueprint-epigenome.eu/index.cfm?p=7BF8A4B6-F4FE-861A-2AD57A08D63D0B58>.

Mapped reads of the ChIP-seq data for H3K4me1 and H3K27ac as well as DNase-seq data from the cell lines GM12878 and H1 were downloaded from the UCSC Genome Browser (GRCh37/hg19 Assembly; <http://genome-euro.ucsc.edu>).

Read density around the 794 CpGs hypermethylated in MM was calculated by seqMINER tool using a 5-kb window upstream and downstream from the CpGs of interest (Ye et al. 2011).

Analysis of transcription factor binding sites

We used ChIP-seq data from the ENCODE Project available at the UCSC Genome Browser (<http://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&g=wgEncodeHaibTfbs>) to obtain information on transcription factor binding sites (TFBS) of a total of 163 TFs. The relative enrichment of each TFBS was calculated for the 794 hypermethylated CpGs located in enhancer elements in comparison with the background. A Fisher's exact test was used, and both an odds ratio and a *P*-value were assigned to each comparison.

Data access

WGBS, HumanMethylation450 BeadChip, and RNA-seq data have been submitted to the European Genome-phenome Archive (<https://www.ebi.ac.uk/ega/>) under accession numbers EGAD00001000672, EGAS00001000841, and EGAS00001001110, respectively. ChIP-seq and DNase-seq data from the U266 cell line have been submitted to the European Nucleotide Archive (<https://www.ebi.ac.uk/ena/>) under sample accession numbers SAMEA2165292 and SAMEA2165299, respectively.

Acknowledgments

We thank C. López-Otín for the critical reading of this manuscript; J.C. Cigudosa for kindly providing the U266 MM cell line; M. Ardanaz, M.P. Rabasa, M. Xirvent, A. Pereda, G. Azaceta, A. Urquía, V. Carrasco, E. Amutio, S. Varea, A. Alfonso, and M.J. Larrayoz for providing the patients' data; and Amaia Vilas for her excellent technical assistance. This work was funded by the European Union's Seventh Framework Programme through the Blueprint Consortium (grant agreement 282510); the Spanish Ministry of Economy and Competitiveness (MINECO) (project SAF2009-08663); grants from Instituto de Salud Carlos III (ISCIII) PI10/01691, PI13/01469, RTICC RD12/0036/0068; and the Fundació La Marató de TV3 (20132130-31-32). X.A. is a Marie Curie researcher under contract "LincMHeM-330598," and J.I. M.-S. is a Ramon y Cajal researcher of the MINECO. M.K. is supported by the AGAUR (Generalitat de Catalunya), and M.P. is supported by a Sara Borrell fellowship CD12/00540.

Author contributions: X.A., G.C., M.K., and J.I.M.-S. analyzed the DNA methylation microarrays. S.H., A.E., A.Me., and E.R. processed and analyzed WGBS data. L.A., J.B., and M.G. performed WGBS library preparation and sequencing. G.C., A.B., N.R., J.H. A.M., R.S., and H.G.S. performed ChIP-seq or analyzed the data. G.C., V.S., F.F., E.G., and A.Me. performed RNA-seq experiments or analyzed the data. N.C.G., M.J.C., E.C., J.S.M., and F.P. reviewed the pathologic and clinical data and confirmed diagnosis. M.P. and M.J.C. coordinated or performed sample preparation and quality control. M.J.C. performed FISH analyses. J.M.G.-V., M.I.R., and E. C.S. performed analysis for studying the nuclear lamina. M.P., J. R.R.-M., and E.S.J.-E. performed functional in vitro experiments. G.C., M.K., A.C.Q., and R.B. functionally characterized differentially methylated regions. D.R., L.C., A.D., and P.F. were in charge of data management. R.S., E.C., A.Me., H.G.S., and I.G.G. coordinated next-generation sequencing efforts and performed primary data analysis. F.P. and J.I.M.-S. conceived the study; X.A., F.P., and J.I.M.-S. led the experiments and wrote the paper.

References

Bergsagel PL, Kuehl WM. 2005. Molecular pathogenesis and a consequent classification of multiple myeloma. *J Clin Oncol* **23**: 6333–6338.

- Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. 2013. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. *Blood* **121**: 884–892.
- Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, Noshmeh H, Lange CP, van Dijk CM, Tollenaar RA, et al. 2011. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. *Nat Genet* **44**: 40–46.
- Busche S, Ge B, Vidal R, Spinella JF, Saillour V, Richer C, Healy J, Chen SH, Droit A, Sinnett D, et al. 2013. Integration of high-resolution methylation and transcriptome analyses to dissect epigenomic changes in childhood acute lymphoblastic leukemia. *Cancer Res* **73**: 4323–4336.
- Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. 2011. Initial genome sequencing and analysis of multiple myeloma. *Nature* **471**: 467–472.
- Chng WJ, Santana-Dávila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, et al. 2006. Prognostic factors for hyperdiploid-multiple myeloma: effects of chromosome 13 deletions and IgH translocations. *Leukemia* **20**: 807–813.
- Ernst J, Kheradpour P, Mikkelson TS, Shores N, Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, et al. 2011. Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature* **473**: 43–49.
- Fang M, Ou J, Hutchinson L, Green MR. 2014. The BRAF oncoprotein functions through the transcriptional repressor MAFK to mediate the CpG Island Methylator phenotype. *Mol Cell* **55**: 904–915.
- Feldmann A, Ivanek R, Murr R, Gaidatzis D, Burger L, Schübeler D. 2013. Transcription factor occupancy can mediate active turnover of DNA methylation at regulatory regions. *PLoS Genet* **9**: e1003994.
- Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, Mu XJ, Khurana E, Rozowsky J, Alexander R, et al. 2012. Architecture of the human regulatory network derived from ENCODE data. *Nature* **489**: 91–100.
- Hansen KD, Timp W, Bravo HC, Sabuncian S, Langmead B, McDonald OG, Wen B, Wu H, Liu Y, Diep D, et al. 2011. Increased methylation variation in epigenetic domains across cancer types. *Nat Genet* **43**: 768–775.
- Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysosfakis G, Schinke C, Tariman J, Vickrey E, et al. 2013. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. *J Immunol* **190**: 2966–2975.
- Hon GC, Rajagopal N, Shen Y, McCleary DF, Yue F, Dang MD, Ren B. 2013. Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. *Nat Genet* **45**: 1198–1206.
- Issa JP. 2004. CpG island methylator phenotype in cancer. *Nat Rev Cancer* **4**: 988–993.
- Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE, Morgan GJ. 2013. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. *Blood* **122**: 219–226.
- Klug M, Rehli M. 2006. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. *Epigenetics* **1**: 127–130.
- Kulis M, Heath S, Bibikova M, Queirós AC, Navarro A, Clot G, Martínez-Trillos A, Castellano G, Brun-Heath I, Pinyol M, et al. 2012. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. *Nat Genet* **44**: 1236–1242.
- Kulis M, Queirós AC, Beekman R, Martín-Subero JI. 2013. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. *Biochim Biophys Acta* **1829**: 1161–1174.
- Kurosaki T, Shinohara H, Baba Y. 2010. B cell signaling and fate decision. *Annu Rev Immunol* **28**: 21–55.
- Lee ST, Xiao Y, Muench MO, Xiao J, Fomin ME, Wiencke JK, Zheng S, Dou X, de Smith A, Chokkalingam A, et al. 2012. A global DNA methylation and gene expression analysis of early human B-cell development reveals a demethylation signature and transcription factor network. *Nucleic Acids Res* **40**: 11339–11351.
- Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, et al. 2013. Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. *PLoS One* **8**: e66982.
- Martin P, Garcia-Cosío M, Santon A, Bellas C. 2008. Aberrant gene promoter methylation in plasma cell dyscrasias. *Exp Mol Pathol* **84**: 256–261.
- Matthias P, Rolink AG. 2005. Transcriptional networks in developing and mature B cells. *Nat Rev Immunol* **5**: 497–508.
- Morgan GJ, Walker BA, Davies FE. 2012. The genetic architecture of multiple myeloma. *Nat Rev Cancer* **12**: 335–348.
- Nojima M, Maruyama R, Yasui H, Suzuki H, Maruyama Y, Tarasawa I, Sasaki Y, Asaoku H, Sakai H, Hayashi T, et al. 2009. Genomic screening for genes silenced by DNA methylation revealed an association between

- RASD1 inactivation and dexamethasone resistance in multiple myeloma. *Clin Cancer Res* **15**: 4356–4364.
- Rivera CM, Ren B. 2013. Mapping human epigenomes. *Cell* **155**: 39–55.
- Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J. 2010. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. *Cancer Res* **70**: 6934–6944.
- San Miguel JF, González M, Gascón A, Moro MJ, Hernández JM, Ortega F, Jiménez R, Guerras L, Romero M, Casanova F, et al. 1991. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. *Br J Haematol* **77**: 185–190.
- Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Schöler A, van Nimwegen E, Wirbelauer C, Oakeley EJ, Gaidatzis D, et al. 2011. DNA-binding factors shape the mouse methylome at distal regulatory regions. *Nature* **480**: 490–495.
- Taberlay PC, Statham AL, Kelly TK, Clark SJ, Jones PA. 2014. Reconfiguration of nucleosome-depleted regions at distal regulatory elements accompanies DNA methylation of enhancers and insulators in cancer. *Genome Res* **24**: 1421–1432.
- Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. 2011. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. *Blood* **117**: 553–562.
- Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. 2006. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with *BRAF* mutation in colorectal cancer. *Nat Genet* **38**: 787–793.
- Whyte WA, Bilodeau S, Orlando DA, Hoke HA, Frampton GM, Foster CT, Cowley SM, Young RA. 2012. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. *Nature* **482**: 221–225.
- Wong KY, Yim RL, So CC, Jin DY, Liang R, Chim CS. 2011. Epigenetic inactivation of the MIR34B/C in multiple myeloma. *Blood* **118**: 5901–5904.
- Ye T, Krebs AR, Choukrallah MA, Keime C, Plewniak F, Davidson I, Tora L. 2011. seqMINER: an integrated ChIP-seq data interpretation platform. *Nucleic Acids Res* **39**: e35.

Received June 20, 2014; accepted in revised form January 22, 2015.

Whole-genome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

Xabier Agirre, Giancarlo Castellano, Marien Pascual, et al.

Genome Res. 2015 25: 478-487 originally published online February 2, 2015

Access the most recent version at doi:[10.1101/gr.180240.114](https://doi.org/10.1101/gr.180240.114)

Supplemental Material

<http://genome.cshlp.org/content/suppl/2015/02/06/gr.180240.114.DC1>

References

This article cites 35 articles, 10 of which can be accessed free at:

<http://genome.cshlp.org/content/25/4/478.full.html#ref-list-1>

Creative Commons License

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Focused on your science.

USC
SCIENTIFIC
SIDE BY SCIENCE

To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>